The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Bhosale's top pick is Prestige Estates Projects with a stoploss of Rs 1,600. "The stock is looking very positive on the daily ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Biocon Biologics, a subsidiary of Biocon, has secured EU marketing authorisation for its Denosumab biosimilars Vevzuo and ...

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Evfraxy is authorised for the treatment of osteoporosis in men with prostate cancer as increased risk of fractures or ...

Indian biosimilars company Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520), today announced that the UK’s ...